ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

Confused about 1st and 2nd line drugs? Here’s a guide!

Renee Parker

Dec 30, 2019
2 min

Confused about 1st and 2nd line drugs? Here’s a guide!

Janet Freeman-Daily

May 16, 2019
1 min

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Janet Freeman-Daily

May 5, 2019
1 min

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Bärbel Söhlke

Apr 16, 2019
2 min

ROS1 News From Europe

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Janet Freeman-Daily

Feb 19, 2019
1 min

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Thinking about a “drug vacation” from crizotinib? Read this first!

Janet Freeman-Daily

Jan 17, 2019
3 min

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 31, 2018
1 min

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 14, 2018
1 min

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 5, 2018
1 min

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 27, 2018
1 min

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Janet Freeman-Daily

Jun 15, 2018
1 min

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Joyce Hoelting

Jan 5, 2017
4 min

ROS1ders Blog

Confused about 1st and 2nd line drugs? Here’s a guide!

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

ROS1 News From Europe

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)